RedChip Weekly Newsletter

T. Rowe Price's Page Sees Value in Small Caps and Emerging Markets in 2019

Smooth sailing for U.S. large cap stocks in 2017 gave way to choppy waters in 2018. That makes the stock market forecast for 2019 a bit tricky.

Sebastien Page, head of T. Rowe Price's multiasset division, said the firm favors small-caps over large-caps for 2019, citing benefits from tax reform and less exposure to trade risk as well as a stronger U.S. dollar.

Read the RedChip Money Report every week to stay on top of the latest developments in small-caps in 2019.

GSRX Industries (OTCQB: GSRX) Receives Establishment License for New Green Spirit RX Medicinal Cannabis Dispensary by Department of Health of Puerto Rico

GSRX Industries (OTCQB: GSRX), through its wholly-owned subsidiary, Project 1493 LLC, has received the establishment license for the Company’s newest Green Spirit RX medicinal cannabis dispensary in Puerto Rico, clearing the way for the dispensary to begin retail operations immediately.

The newest Green Spirit RX medicinal cannabis dispensary is located at Bo. Quebrada de Fajardo, Carr. #3 Km. 44.9. At nearly 5,000 square feet, GSRX’s Fajardo medicinal cannabis dispensary will be one of the island’s largest. Upon opening, it will become the Company’s fifth medicinal cannabis dispensary in Puerto Rico.

The Backstory: GSRX Industries (OTCQB: GSRX), through its subsidiaries, is in the business of acquiring, developing and operating retail cannabis dispensaries, and is in the process of expanding its business to include the cultivation, extraction, manufacture and delivery of cannabis and cannabinoid products. Currently, GSRX operates five cannabis dispensaries in Puerto Rico, operates one dispensary in California, and has four additional pre-qualified locations in Puerto Rico, all of which are in various phases of development and construction.

Disclosure

GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services and 50,000 shares for investor awareness services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.

Axon Enterprise (NASDAQ: AAXN), Formerly Known As Taser, Acknowledges Validity of Digital’s Auto-Activation ’292 Patent by Dismissing Its Appeal

Digital Ally (NASDAQ: DGLY) which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, is pleased to announce a major victory in its legal battles against Axon Enterprise, (NASDAQ: AAXN, formerly known as Taser International). After losing its validity challenge at the U.S. Patent Office for Digital Ally’s Patent No. 8,781,292 (“the ’292 Patent”), Axon has decided to abandon its appeal and discontinue all remaining attacks against the ’292 Patent.

Key Quote: "This decision was a major triumph for our team at Digital who worked so hard to develop this auto-activation technology.” Digital Ally CEO Stanton Ross

The Backstory: Digital Ally develops, manufactures, and markets advanced technology products for law enforcement, homeland security, and commercial applications. The Company's primary focus is digital video imaging and storage. The Company is headquartered in Lenexa, Kansas.

Disclosure

Digital Ally (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.

Interpace Diagnostics (NASDAQ: IDXG) Ranked As Top 10 Bioinformatics Solutions Provider

Interpace Diagnostics Group (NASDAQ: IDXG), announced that CIO Applications, a publication focused on providing professionals with information on the most comprehensive collection of technology trends, has once again recognized Interpace Diagnostics as a top bioinformatics solutions company. In 2018 CIO Applications ranked Interpace as a Top 10 Company for providing bioinformatics solutions through the Company’s extensive database of molecular testing results.

Key Quote: “We were pleased to be recognized again by CIO Applications as a top bioinformatics solutions provider and especially now as a top 10 provider recognizing the value of our core biomarker and DNA analysis as well as our biobank and associated databases.” Jack Stover, President and CEO of Interpace

The Backstory: Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular and related first line diagnostic tests and pathology services for evaluating the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDx™, that differentiates lung cancer of primary vs. metastatic origin.

Quote of the Week

”Knowing when to sell a winner can be a very elusive skill. It often makes sense to keep a small percentage of the shares for idiot's insurance."
-Byron Roth, ROTH Capital

Lesson of the Week

What insider buying may tell you.
Read More

Latest Videos